![]() |
市场调查报告书
商品编码
1466074
连续血糖监测系统市场:按组件、人口统计、患者类型、最终用户、分销管道 - 全球预测 2024-2030Continuous Glucose Monitoring Systems Market by Component (Integrated Insulin Pumps, Sensors, Transmitters & Receivers), Demographics (Adult Population, Children Population), Patient Type, End User, Distribution Channel - Global Forecast 2024-2030 |
※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。
预计2023年连续血糖监测系统市场规模为55.4亿美元,预计2024年将达62.1亿美元,2030年将达到125.5亿美元,复合年增长率为12.37%。
连续血糖监测系统 (CGMS) 是一种先进的医疗设备,旨在定期(通常每隔几分钟、每天 24 小时、一年 365 天)提供即时血糖读数。这些系统由小型感测器组成,可将资料无线传输到专用接收器、智慧型手机、智慧型手錶或其他显示设备,使用户无需进行传统的手指血液测试即可监测血糖浓度。全球糖尿病患者数量不断增加,以及人们日益认识到连续血糖值监测优于传统血糖监测,推动了市场成长。然而,该设备的高价格和缺乏统一报销可能会限制市场渗透。由于设备校准问题和外部因素干扰导致的葡萄糖测量不准确也是一个挑战。此外,利用巨量资料和进阶分析来提高预测能力、个人化和临床结果,为市场成长创造了潜在的机会。
主要市场统计 | |
---|---|
基准年[2023] | 55.4亿美元 |
预测年份 [2024] | 62.1亿美元 |
预测年份 [2030] | 125.5亿美元 |
复合年增长率(%) | 12.37% |
组件 在 CGM 系统中增加使用发射器和接收器进行即时血糖监测
整合胰岛素帮浦是一种根据设定的基础血糖值自动输送胰岛素的设备,并与连续血糖监测 (CGM) 系统配合使用。胰岛素帮浦根据即时血糖测量调整胰岛素输送。这项功能极大地有助于糖尿病患者血糖值的无缝管理,对于需要强化胰岛素治疗的患者和 1 型糖尿病患者尤其有用。该感测器是 CGM 系统的重要组成部分,因为它是测量皮下间质液中血糖浓度的组件。 CGM 感测器通常需要每 7 到 14 天更换一次,具体取决于型号。想要最小侵入和较长佩戴时间的患者更喜欢长寿命感测器。发送器是 CGM 系统的一部分,用于将即时血糖资料从感测器传输到接收器和智慧型装置。接收器是显示葡萄糖资料的装置。有些患者喜欢允许他们使用智慧型手机作为接收器的系统,而有些患者如果不喜欢使用智慧型设备,则喜欢专用设备。
人口统计:更有效、更侵入性的儿童用CGM 系统的持续进步
连续血糖监测 (CGM) 系统对于成年人极为重要,尤其是那些被诊断出患有第 1 型或第 2 型糖尿病的成年人。成年人需要持续准确地监测血糖值,以有效管理自己的病情并预防与糖尿病相关的急性和长期併发症。儿童用CGM 系统根据儿童人群独特的生理和生活方式要求,在尺寸、灵敏度和易用性方面进行了专门设计。这些设备可帮助父母和看护者更有效地监测和管理孩子的糖尿病,让他们安心并提高生活品质。
患者类型:CGM 系统在第 1 型糖尿病患者中的重要性日益增加:准确度高、时滞短、血糖快速变化的预测警报
由于胰臟中产生胰岛素的 β 细胞受到自体免疫破坏,1 型糖尿病患者依赖外部胰岛素。连续血糖监测(CGM)系统为这群人提供了便利,也是血糖浓度管理的重要工具。这些患者需要即时资料来准确调整胰岛素剂量。 CGM 系统比传统血糖监测具有显着优势,可以详细了解血糖趋势,从而更好地控制血糖并降低低血糖风险。 2 型糖尿病患者应监测血糖浓度,尤其是在服用磺酰尿素或Meglitinides药物时,这些药物并不总是需要胰岛素,但会增加低血糖的风险。 2型糖尿病的CGM旨在管理生活习惯,除了药物治疗外,还包括饮食和运动疗法。随着 CGM 技术变得越来越便宜,并且越来越多的证据表明它可以帮助改善未接受胰岛素治疗的患者的血糖控制,CGM 的使用在这群人中变得越来越普遍。
最终用户:具有远端资料共用功能的家庭患者越来越偏好 CGM 系统
诊断中心和诊所是连续血糖监测 (CGM) 系统部署的重要组成部分。这些设施通常是出现糖尿病症状或需要持续监测诊断病情的患者的第一个接触点。家庭医疗保健是 CGM 系统快速成长的领域,因为越来越多的糖尿病患者更喜欢在舒适的家中管理糖尿病。这些设备非常方便,可以进行连续监测,而无需频繁拜访您的医疗保健提供者。加护病房(ICU) 是一个至关重要的环境,病患需要随时密切监测,包括血糖浓度。 ICU CGM 系统需要可靠并与其他监测设备集成,以全面了解患者的健康状况。
区域洞察
以美国和加拿大为中心的美洲地区是 CGM 系统的强大市场,并得到高购买力和采用最新技术的成熟医疗保健系统的支持。美国和加拿大在CGM技术领域处于领先地位,有许多公司在研究和开发新系统,该领域申请的专利数量证明了这一点。美国消费者更有可能维持健康的生活方式,并将个人健康科技融入日常生活中。大量投资和保险覆盖促进了 CGM 系统的使用,使公众更容易使用它们。欧盟(EU)国家对 CGM 系统表现出强劲需求,该系统得到广泛认可,促进糖尿病生活方式管理,并得到有利的保险报销方案的支持。欧盟的医疗设备产业受到严格监管,确保产品品质和安全的高标准。德国、法国和英国等国家是实施 CGM 系统的领先国家。中东地区,特别是波湾合作理事会(GCC)国家,人均医疗保健支出较高,并且正在迅速采用先进的医疗保健技术。由于糖尿病盛行率不断上升以及人们对糖尿病的认识不断提高,亚太地区对 CGM 系统的需求正在迅速增长。用于健康监测的可穿戴技术的日益普及表明亚太地区消费者对方便且非侵入式医疗保健设备的广泛需求。
FPNV定位矩阵
FPNV定位矩阵对于评估连续血糖监测系统市场至关重要。我们检视与业务策略和产品满意度相关的关键指标,以对供应商进行全面评估。这种深入的分析使用户能够根据自己的要求做出明智的决策。根据评估,供应商被分为四个成功程度不同的像限:前沿(F)、探路者(P)、利基(N)和重要(V)。
市场占有率分析
市场占有率分析是一种综合工具,可以对连续血糖监测系统市场供应商的现状进行深入而详细的研究。全面比较和分析供应商在整体收益、基本客群和其他关键指标方面的贡献,以便更好地了解公司的绩效及其在争夺市场占有率时面临的挑战。此外,该分析还提供了对该行业竞争特征的宝贵见解,包括在研究基准年观察到的累积、分散主导地位和合併特征等因素。这种详细程度的提高使供应商能够做出更明智的决策并制定有效的策略,从而在市场上获得竞争优势。
1. 市场渗透率:提供有关主要企业所服务的市场的全面资讯。
2. 市场开拓:我们深入研究利润丰厚的新兴市场,并分析其在成熟细分市场的渗透率。
3. 市场多元化:提供有关新产品发布、开拓地区、最新发展和投资的详细资讯。
4. 竞争评估和情报:对主要企业的市场占有率、策略、产品、认证、监管状况、专利状况和製造能力进行全面评估。
5. 产品开发与创新:提供对未来技术、研发活动和突破性产品开发的见解。
1.连续血糖监测系统市场的市场规模与预测是多少?
2.在连续血糖监测系统市场的预测期间内,有哪些产品、细分市场、应用和领域需要考虑投资?
3.连续血糖监测系统市场的技术趋势和法规结构是什么?
4.连续血糖监测系统市场主要供应商的市场占有率为何?
5. 进入血糖连续监测系统市场合适的型态和策略手段是什么?
[191 Pages Report] The Continuous Glucose Monitoring Systems Market size was estimated at USD 5.54 billion in 2023 and expected to reach USD 6.21 billion in 2024, at a CAGR 12.37% to reach USD 12.55 billion by 2030.
Continuous Glucose Monitoring Systems (CGMS) are advanced medical devices designed to provide real-time glucose readings at regular intervals, typically every few minutes, 24/7. These systems comprise a small sensor that transmits the data wirelessly to a display device, which could be a dedicated receiver, a smartphone, or a smartwatch, enabling the user to monitor their glucose levels without the requirement of traditional fingerstick blood tests. The growing preponderance of diabetes across the globe and the rising awareness of the benefits of continuous glucose monitoring over traditional blood glucose monitoring are driving the market growth. However, devices' high prices and lack of uniform reimbursement can limit market penetration. Inaccuracies in glucose readings due to device calibration issues or interference from external factors also pose a challenge. Furthermore, leveraging big data and advanced analytics to improve predictive capabilities, personalization, and clinical outcomes creates potential opportunities for market growth.
KEY MARKET STATISTICS | |
---|---|
Base Year [2023] | USD 5.54 billion |
Estimated Year [2024] | USD 6.21 billion |
Forecast Year [2030] | USD 12.55 billion |
CAGR (%) | 12.37% |
Component: Increasing utilization of transmitters & receivers in CGM systems for real-time glucose monitoring
Integrated insulin pumps are devices that deliver insulin automatically based on the set basal rate and work in conjunction with continuous glucose monitoring (CGM) systems. They adjust the insulin delivery based on real-time glucose readings. This feature greatly contributes to the seamless management of blood glucose levels in diabetes patients, especially useful for those with intensive insulin therapy needs or those with Type 1 diabetes. Sensors are a crucial part of CGM systems, as they are the components that measure levels of glucose in the interstitial fluid beneath the skin. CGM sensors typically require changing every 7 to 14 days, depending on the model. Patients who desire minimal intrusion and longer wear times prefer sensors with extended life spans. The transmitter is the part of the CGM system that sends real-time glucose data from the sensor to a receiver and smart device. The receiver is the device that displays the glucose data. Some patients prioritize a system that allows the use of their own smartphone as a receiver, whereas others prefer a dedicated device if they are not comfortable using smart devices.
Demographics: Ongoing advancements in children CGM systems to make it more effective and less invasive
Continuous Glucose Monitoring (CGM) systems are crucial for the adult population, especially those diagnosed with Type 1 or Type 2 diabetes. Adults require consistent and accurate monitoring of their blood glucose levels to manage their condition effectively and to prevent acute and long-term complications associated with diabetes. CGM systems for children are designed with special considerations for size, sensitivity, and ease of use, owing to the unique physiological and lifestyle requirements of the pediatric population. These devices help parents and caregivers monitor and manage their child's diabetes more effectively, providing peace of mind and improved quality of life.
Patient Type: Rising significance of CGM system in Type 1 diabetes patient for high accuracy, minimal lag time, and predictive alerts for rapid glucose changes
Patients with Type 1 diabetes rely on external insulin because of the autoimmune destruction of the insulin-producing beta cells in the pancreas. Continuous Glucose Monitoring (CGM) systems for this group provide convenience and crucial tools for the management of glucose levels. These patients need real-time data to adjust insulin doses accurately. CGM systems offer significant advantages over traditional blood glucose monitoring, providing detailed insights into glucose trends, which results in better glycemic control and reduction of hypoglycemia risk. Type 2 diabetes patients might not always require insulin but still need to monitor their glucose levels, especially if they are on sulfonylureas and meglitinides, which increase the risk of hypoglycemia. CGM for Type 2 diabetes is geared towards lifestyle management, including diet and exercise, alongside medication. The use of CGM is progressively becoming more common in this group as the technology becomes more affordable and as evidence mounts that it can help improve glycemic control in non-insulin-treated patients.
End User: Growing preference of CGM systems by home patients with remote data sharing capabilities
Diagnostic centers and clinics represent a significant segment for the deployment of Continuous Glucose Monitoring (CGM) systems. These facilities often serve as the initial point of contact for patients experiencing symptoms of diabetes and for those who require ongoing monitoring for their diagnosed condition. Home healthcare represents a rapidly growing segment for CGM systems, as an increasing number of patients with diabetes prefer to manage their condition in the comfort of their own homes. These devices offer convenience and allow for continuous monitoring without the need to visit a healthcare provider frequently. Intensive Care Units (ICUs) are critical settings wherein patients require constant and close monitoring, including for their glucose levels. CGM systems in ICUs must be highly reliable and capable of integrating with other monitoring equipment to ensure a holistic view of a patient's health status.
Regional Insights
The Americas, led by the United States and Canada, show a strong market for CGM systems, aided by higher purchasing power and well-established healthcare systems implementing the latest technologies. The United States & Canada are prominent in CGM technology, with numerous companies researching and developing new systems, evident from a high number of patents filed in this domain. Consumers in the United States have shown an inclination towards maintaining healthy lifestyles, integrating personal health technology with everyday living. There is significant investment and insurance coverage that promotes the use of CGM systems, making them more accessible to the population. European Union countries demonstrate a robust demand for CGM systems, broadly supported by widespread awareness, a push for lifestyle management of diabetes, and favorable insurance reimbursement scenarios. The European Union's medical device sector is tightly regulated, ensuring high standards of product quality and safety. Countries including Germany, France, and the UK are leaders in the adoption of CGM systems. The Middle East, particularly the Gulf Cooperation Council (GCC) countries, has high per capita healthcare spending and is rapidly adopting advanced technologies in healthcare. Asia Pacific is undergoing a surge in the demand for CGM systems due to the increasing prevalence of diabetes and heightened awareness about the disease. The rising popularity of wearable technology for health monitoring indicates a broad consumer need for convenient and non-intrusive healthcare devices in the APAC region.
FPNV Positioning Matrix
The FPNV Positioning Matrix is pivotal in evaluating the Continuous Glucose Monitoring Systems Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Continuous Glucose Monitoring Systems Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Key Company Profiles
The report delves into recent significant developments in the Continuous Glucose Monitoring Systems Market, highlighting leading vendors and their innovative profiles. These include A. Menarini Diagnostics s.r.l, Abbott Laboratories, AgaMatrix Inc. by I-Sens Inc., Ascensia Diabetes Care Holdings AG, Dexcom, Inc., F. Hoffmann-La Roche Ltd., Insulet Corporation, Johnson & Johnson Services, Inc., Medtronic PLC, Medtrum Technologies Inc., Nemaura Medical Inc., Novo Nordisk A/S, NXP Semiconductors N.V., Senseonics Holdings Inc., Sibionics, STMicroelectronics N.V., Tandem Diabetes Care, Inc., Texas Instruments Incorporated, and Ypsomed Holding AG.
Market Segmentation & Coverage
1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
1. What is the market size and forecast of the Continuous Glucose Monitoring Systems Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Continuous Glucose Monitoring Systems Market?
3. What are the technology trends and regulatory frameworks in the Continuous Glucose Monitoring Systems Market?
4. What is the market share of the leading vendors in the Continuous Glucose Monitoring Systems Market?
5. Which modes and strategic moves are suitable for entering the Continuous Glucose Monitoring Systems Market?